Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P980044/S067

SUPARTZ FX

Seikagaku Corp. · Decision date Sep 4, 2026

MEDTECHLEDGER EXPLANATIONP980044/S067

What did the FDA approve?

The FDA database lists decision APPR dated 2026-09-04 for supplement S067 under PMA P980044, product SUPARTZ FX. The supplement is a 135 Review Track For 30-Day Notice with reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. As stated, it approves replacing one of two existing isolators used for sterility testing of SUPARTZ FX with a new isolator equipped with an integrated hydrogen peroxide decontamination system.

The supplied fields establish the supplement-to-PMA link through the P980044 identifier; the notice covers a manufacturing change, not a new approval of the whole device. The statement gives the changed item and its decontamination method but does not describe validation data, performance of the new isolator, or any resulting effect on the product. No clinical or sterility-testing outcomes are reported, and the stated purpose is not independent evidence of safety or effectiveness. The terms of the 30-day notice review are not detailed here.

FDA approval order statement

Approval to replace one of two existing isolators used for sterility testing of SUPARTZ FX with a new isolator equipped with an integrated hydrogen peroxide decontamination system.
Regulatory pathway
PMA supplement
Supplement type
135 Review Track For 30-Day Notice
Clinical specialty
Orthopedic
Decision date
Sep 4, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P980044/S067
Regulatory pathway
PMA supplement
Product code
MOZ
Decision code
APPR
Decision date
Sep 4, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Acid, hyaluronic, intraarticular.

Product code
MOZ
FDA device class
3

For the original device and its historical approval scope, see PMA P980044. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P980044/S067 received

    Application receipt date recorded by FDA.

  2. P980044/S067 · FDA decision

    135 Review Track For 30-Day Notice

Timeline entries are records held by MedtechLedger for P980044. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P980044

Product / regulatory recordCompanyPathwayDecision dateSource
SUPARTZ FXP980044
Seikagaku Corp.PMA approvalJan 24, 2001FDA

Explore the linked device profile

Other records with product code MOZ

Product / regulatory recordCompanyPathwayDecision dateSource
Gel-OneP080020/S056
Seikagaku Corp.PMA supplementSep 4, 2026FDA
Ferring Pharmaceuticals, Inc.PMA supplementSep 2, 2026FDA
GEL-ONEP080020
Seikagaku Corp.PMA approvalMar 22, 2011FDA
Ferring Pharmaceuticals, Inc.PMA approvalDec 3, 2004FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Seikagaku Corp.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6-1, Marunouchi 1-Chome,, Chiyoda-Ku, Tokyo, 100-0005

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records